Evaluation of the SpeeDxResistancePlus®GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin inNeisseria gonorrhoeae

Hadad, Ronza; Cole, Michelle; Ebeyan, Samantha; Jacobsson, Susanne; Yeen Tan, Lit; Golparian, Daniel; Erskine, Simon; Day, Michaela; M. Whiley, David; Unemo, Magnus; European collaborative group, the; Abad Torreblanca, Raquel; Rós Ásmundsdóttir, Lena; Balla, Eszter; De Baetselier, Irith; Berçot, Béatrice; Bergheim, Thea; José Borrego, Maria; Buder, Susanne; Cassar, Robert; Cole, Michelle; P. van Dam, Alje; Eder, Claudia; Hoffmann, Steen; Hunjak, Blaženka; Jeverica, Samo; Kirjavainen, Vesa; Maikanti-Charalambous, Panayiota; Miriagou, Vivì; Młynarczyk-Bonikowska, Beata; Pakarna, Gatis; Pavlik, Peter; Perrin, Monique; Pett, Joseph; Stefanelli, Paola; Templeton, Kate; Unemo, Magnus; Viktorova, Jelena; Zákoucká, Hana

doi:10.1093/jac/dkaa381

Public

Evaluation of the SpeeDxResistancePlus®GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin inNeisseria gonorrhoeae

Published in Journal of Antimicrobial Chemotherapy • Aug 14, 2020

Authors:

Ronza Hadad

Michelle Cole

Samantha Ebeyan

Abstract

BACKGROUND: Accurate molecular assays for prediction of antimicrobial resistance (AMR)/susceptibility in Neisseria gonorrhoeae (Ng) can offer individualized treatment of gonorrhoea and enhanced AMR surveillance. OBJECTIVES: We evaluated the new ResistancePlus® GC assay and the GC 23S 2611 (beta) ass...

Subject

Neisseria gonorrhoeae

Ciprofloxacin

Azithromycin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!